Full history for every metric is available with a Kvantra account
Leap Therapeutics, Inc. (LPTX)
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 10 | 2 | 0 | 0 | 0 | 0 | 0 |
| Operating profit | $m | -37 | -18 | |||||
| Net profit | $m | -3 | -41 | -55 | -81 | -68 | 5 | - |
| EPS reported | $ | 0.07 | - | |||||
| Operating cashflow per share | $ | -0.66 | -0.37 | |||||
| Capex per share | $ | 0.00 | 0.01 | |||||
| FCF per share | $ | -0.66 | -0.36 | |||||
| Free cash flow | $m | -44 | -64 | |||||
| Net debt | $m | -14 | -8 | |||||
| Book value equity | $m | 154 | 139 | |||||
| Book value per share | $ | 2.17 | 0.79 | |||||
| Number of shares | m | 70.67 | 176.26 | |||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Value | ||||||||
| P/E TTM | x | 17.01 | 1.47 | |||||
| P/B LTM | x | 0.76 | 0.23 | |||||
| P/S LTM | x | 0.00 | 152.42 | |||||
| P/FCF LTM | x | -2.65 | -0.50 | |||||
| EV/EBITDA LTM | x | -2.80 | -1.36 | |||||
| EV/Sales LTM | x | 0.00 | 115.94 | |||||
| Earnings Yield LTM | % | 5.88% | 68.03% | |||||
| FCF Yield | % | -37.71% | -200.44% | |||||
| Quality | ||||||||
| ROE | % | 3.14% | 23.83% | |||||
| ROIC | % | -11.02% | -12.58% | |||||
| Operating margin | % | 0.00% | -8504.8% | |||||
| Gross margin | % | 0.00% | -9631.6% | |||||
| FCF/Sales | % | - | -30551.2% | |||||
| Growth and momentum | ||||||||
| EPS Growth YoY | % | - | - | |||||
| Sales Growth YoY | % | - | -10.68% | |||||
| Net Income Growth YoY | % | - | - | |||||
| FCF Growth | % | - | - | |||||
| Operating Profit Growth | % | - | - | |||||
| Dividend and capital structure | ||||||||
| Dividend Yield | % | 0.00% | 0.00% | |||||
| Dividend Growth | % | 0.00% | 0.00% | |||||
| Payout Ratio | % | 0.00% | 0.00% | |||||
| FCF/Debt | x | -1,155.32 | -1,680.32 | |||||
| Net Debt/EBITDA | x | 0.38 | 0.43 | |||||
| EBIT/Net interest | x | -1,522.50 | 8,887.50 | |||||
| Net debt/market cap | % | -12.02% | -23.93% | |||||
| Net debt/Equity | x | -0.09 | -0.05 | |||||
| Gross debt/equity | x | 0.00 | 0.00 | |||||
Company overview
Leap Therapeutics, Inc. is a biopharmaceutical firm dedicated to discovering and advancing treatments for various cancers. At the forefront of its pipeline is DKN-01, a monoclonal antibody designed to block Dickkopf-related protein 1 (DKK1). This investigational therapy is currently undergoing several clinical trials, targeting a range of malignancies such as esophagogastric, hepatobiliary, gynecologic, and prostate cancers. Leap Therapeutics has also forged an option and licensing partnership with BeiGene, Ltd., granting them rights to develop and market DKN-01 across Asia (excluding Japan), Australia, and New Zealand. Established in 2011, the company initially operated as HealthCare Pharmaceuticals, Inc., before rebranding to Leap Therapeutics, Inc. in November 2015. Its corporate headquarters are situated in Cambridge, Massachusetts.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Leap Therapeutics, Inc. (LPTX)
Leap Therapeutics, Inc. is a biopharmaceutical firm dedicated to discovering and advancing treatments for various cancers. At the forefront of its pipeline is DKN-01, a monoclonal antibody designed to block Dickkopf-related protein 1 (DKK1). This investigational therapy is currently undergoing several clinical trials, targeting a range of malignancies such as esophagogastric, hepatobiliary, gynecologic, and prostate cancers. Leap Therapeutics has also forged an option and licensing partnership with BeiGene, Ltd., granting them rights to develop and market DKN-01 across Asia (excluding Japan), Australia, and New Zealand. Established in 2011, the company initially operated as HealthCare Pharmaceuticals, Inc., before rebranding to Leap Therapeutics, Inc. in November 2015. Its corporate headquarters are situated in Cambridge, Massachusetts.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free